Johnson & Johnson Innovative Medicine (J&J) addressed the potential impact of pharmaceutical tariffs during its Q1 2025 earnings call, as the US government intensifies its scrutiny of foreign drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback